on-invasive assessment of lung remodeling in patients with idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH) using [11C]-Nintedanib or [18F]-FLT PET imaging.

Recruiting

• Conditions: idiopatic pulmonary fibrosis; pulmonary arterial hypetrension; 10037454

• Registration Number: NL-OMON44254
• Lead Sponsor: Vrije Universiteit

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 90

Inclusion Criteria

In order to be eligible to participate in this study, a subject must meet all of the following criteria:
1. Diagnosis of IPF, according to ATS/ERS guidelines (ref Raghu AJRCCM 2011)
or
Diagnosis of PAH, according to ESC/ERS guidelines (ref: Galie ERJ 2015)
or
Unaffected BMPR2 mutation carrier
or
Normal control subjects
2. Age >18 and <80 years

Exclusion Criteria

- Claustrophobia
- Inability to provide informed consent
- In case of IPF patients: pulmonary hypertension suspected by echocardiography or proven by right heart
catheterization
- In case of PAH patients: TLC < 70%pred or radiographic evidence of interstitial lung disease
- In case of BMPR2 mutation carriers and normal control subjects, one or more of the following: abnormal
spirometry, TLC < 70%, echocardiographic evidence of pulmonary hypertension

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Uptake of [11C]-Nintedanib or [18F]-FLT in the lung of IPF or IPAH patients.<br /><br>Secundary study</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>none</p><br>